After Skylar Sylvester ’14, D.V.M. ’18, first treated Indy, a six-year-old puggle-Boston terrier mix, for lymphoma in 2018 as a fourth-year student at the College of Veterinary Medicine, she didn’t expect to see her again.

“Knowing that the prognosis for lymphomas in dogs is typically about a year after chemotherapy treatment, I said goodbye to Indy before I left for Philadelphia,” said Sylvester, who returned to the Cornell University Hospital for Animals in 2019 to start her medical oncology residency after a rotating internship at the University of Pennsylvania School of Veterinary Medicine. “When I came back for residency to see her still here and thriving and happy, I was so grateful.”

Credit: Provided

Indy continues to defy the odds. Over the past three years, she has been treated with different chemotherapies five times and gone into remission each time. She is now 9 years old, in her fifth remission, and doing well.

“She’s like a miracle dog,” said Dr. Brittany Zumbo, one of the medical oncology residents who cared for Indy. “No one would have expected her to do as well as she has. She must have a lymphoma that’s just less aggressive and a little bit more responsive to these chemotherapies because she is not building up the typical resistance that we can see when we treat lymphoma over and over again.”

Initially, Indy received the typical chemotherapy protocol for lymphoma – cyclophosphamide, hydroxydaunorubicin, Oncovin and prednisone (CHOP). When she came out of remission a year later, the team tried Tanovia (rabacfosadine), a newer drug and the only one that is FDA-approved specifically for dogs with cancer. Indy had a great response to that, with a six-month remission. Treatment with doxorubicin was next, followed by the MOPP protocol – Mustargen, Oncovin, procarbazine and prednisone. When that stopped working, she was put back on the Tanovia.

“We’ve just had a lot of leeway in her treatment,” Sylvester said. “She’s had a variety of what we call ‘rescue’ chemotherapy protocols, which just means that we try something else when one thing stops working.” Currently, Indy sees the doctors at CUHA every other week.

For Indy’s owner, paying for cancer treatments on and off over the course of three years has been challenging. Even though she and her husband have pet insurance, this doesn’t always cover everything, and reimbursements for up-front costs take time to process.

They asked Indy’s main doctor at the time, Dr. Joshua Henry, about financial options. Henry recommended them for a grant from the Petco Foundation and Blue Buffalo Treatment Support Fund to help defray costs. The Petco Foundation and Blue Buffalo first partnered with Cornell in 2016 to help subsidize cancer therapies for owners who otherwise could not afford them. Since then, the foundation has contributed $575,000 to Cornell, enabling more than 200 families to pursue treatments that can be very expensive.

The support fund has provided assistance for every one of Indy’s treatments since then, her owner said.

The oncologists who have treated Indy have been buoyed to see her continued response. “We all feel so fortunate to see her grow older because she was only six when she started treatment. It’s nice to see her face going gray,” Sylvester said.

Indy’s case shows that in some situations, veterinarians can help make cancer a chronic disease that pets can live with for an extended period of time. “She’s a great example of that, and one that has touched everyone in our department,” Sylvester said. “She brings a smile to all of our faces.”

Christina Frank is a freelance writer for the College of Veterinary Medicine.